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Oral Administration of Poly-c-Glutamate
Ameliorates Atopic Dermatitis in Nc/Nga Mice
by Suppressing Th2-Biased Immune Response and
Production of IL-17A
Tae-Young Lee1,5, Doo-Jin Kim1,5, Ji-Na Won1, Il-Han Lee2, Moon-Hee Sung3 and Haryoung Poo1,4
Atopic dermatitis (AD) is a chronic inflammatory skin disease that is closely related to dysregulation of the
T helper type 1 and 2 (Th1)/Th2 balance. A previous study showed that high molecular mass poly-g-glutamate
(g-PGA) isolated from Bacillus subtilis sp. Chungkookjang induces the production of IL-12 from dendritic cells
(DCs). Here, we investigated the effect of g-PGA on AD–like skin disease using an Nc/Nga mouse model. In vitro,
g-PGA activated DCs and induced IL-12 production in mice. In vivo, oral administration of g-PGA markedly
reduced the AD symptoms, similar to the response seen in the dexamethasone (Dex)-treated group. Treatment
with g-PGA also decreased the serum levels of IgG1, the skin levels of Th2 cytokines, the extent of skin
inflammation, and the accumulation of mast cells. Furthermore, g-PGA was effective against established AD,
significantly decreasing serum IgE and Th2 cytokines in the inflamed tissue. Interestingly, the production of IL-17A
in splenocytes was also suppressed by g-PGA, indicating that it inhibits both Th2 and Th17 immune responses.
Collectively, these results suggest that oral administration of g-PGA could be a therapeutic strategy for treating
AD via the modulation of Th2-biased immune responses in an Nc/Nga mouse model.
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INTRODUCTION
Atopic dermatitis (AD) is a complex chronic skin inflammation
that is characterized by subacute pruritus and eczema. It has a
worldwide prevalence of 10–20% and is rapidly increasing in
industrialized countries, making it a major public health
problem, especially among children (Sampson, 1992; Leung,
1997). Although the etiology of AD is not yet fully understood,
studies on its pathogenesis have revealed that AD is highly
associated with the dysregulation of the immune system. In
particular, Th2–polarized immune responses, such as IL-4, IL-
13, and IgE, have critical roles in the pathogenesis of human
AD (Leung and Soter, 2001). Recently, it was found that
filaggrin loss-of-function mutation is closely related to AD
prevalence in human but its interaction with immunological
dysregulation of AD has not been clearly understood (Palmer
et al., 2006; McAleer and Irvine, 2013).
On the basis of the immunopathology of AD, diverse drugs
have been developed to treat the disease. Corticosteroids,
which are efficacious in both acute and chronic AD, suppress
the production of proinflammatory cytokines and chemokines
by binding to cytoplasmic glucocorticoid receptors in the
target cells (Hughes and Rustin, 1997; Charman and
Williams, 2003). Calcineurin inhibitors, such as tacrolimus
and pimecrolimus, have also been utilized to inhibit the
activation of T cells and mast cells in AD lesions (Bornhovd
et al., 2001; Crabtree, 2001). Despite their potent effects,
there have been concerns about the side effects of
corticosteroids and immunosuppressive drugs, which
include skin atrophy, suppression of the hypothalamic-
pituitary-adrenal axis, and the potential for lymphoma
(Barnetson and White, 1992; Arellano et al., 2007).
Although recently developed biological drugs, including
IgE–neutralizing antibodies and tumor necrosis factor block-
ers, have been shown to ameliorate AD efficiently (Milgrom
et al., 1999; Thaiwat and Sangasapaviliya, 2011), the long-
term use of the these drugs is economically infeasible. Thus,
we need novel therapies for AD.
Poly-g-glutamate (g-PGA) is a polymer of glutamic acids
linked by isopeptide bonds (Oppermann-Sanio and Stein-
buchel, 2002). It is naturally produced by a few Gram-
positive bacteria, including Bacillus and Staphylococcus,
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and occurs over a wide range of molecular weights (160–
1,500 kDa) (Candela and Fouet, 2006). It is believed that g-
PGA functions as a protective barrier and stores nutrient
precursors needed for bacterial metabolism (Schreier, 1993).
As g-PGA is biodegradable and abundant in diverse fermented
soybean foods, it is considered safe for human use (Buescher
and Margaritis, 2007). Recently, it was found that high-
molecular-weight (42,000 kDa) g-PGA could stimulate den-
dritic cells (DCs) to produce IL-12 in vitro and exhibited
antitumor activity in vivo (Kim et al., 2007; Lee et al., 2009).
These results suggested that g-PGA may be a T helper type 1
(Th1)–biasing immune modulator, and various studies have
examined its use as an immune modulator or a vaccine
adjuvant (Uto et al., 2007; Okamoto et al., 2012).
A few murine models that spontaneously develop AD–like
skin disease have been established. Nc/Nga mice carry
genetic mutations closely associated with the consitututive
activation of JNK 3 and enhanced IL-4 receptor signaling
(Matsumoto et al., 1999). The mice with dermatitis exhibit
increases in serum IgE, Th2–polarized CD4þ T cells, and
infiltration of mast cells in the skin (Kondo, 1973; Vestergaard
et al., 1999; Kohara et al., 2001). As the pathological and
immunological phenomena in Nc/Nga mice strongly resemble
the observations in AD patients, these mice have been widely
utilized for the study on human AD (Suto et al., 1999). The
flaky tail (ft/ft) mouse is an another spontaneous animal AD
model that was firstly introduced about 50 years ago (Lane,
1972). As the flaky tail mice have filaggrin mutation and this
genetic defect is often associated with AD in human, they are
considered as corresponding animal model for human AD
(Moniaga et al., 2010).
In this study, we investigated the effect of g-PGA on the
spontaneous AD observed in the Nc/Nga mouse model.
Under conventional conditions, control Nc/Nga mice devel-
oped spontaneous AD characterized by increased serum
IgE and skin inflammation. However, oral administration of
g-PGA significantly alleviated these AD–like symptoms and
lowered the indicators of the Th2–type immune response,
including IgE levels and the IgG1/IgG2a ratio. These results
indicate that g-PGA is an active immune modulator that is
capable of suppressing the Th2 response and may be a good
candidate as a therapeutic agent for human AD.
RESULTS
c-PGA activates DCs to produce IL-12 in the Nc/Nga mouse
model
It was previously reported that g-PGA induces activation of
immature DCs and exhibits antitumor activity in a C57BL/6
mouse system (Lee et al., 2009). To test whether g-PGA
activates DCs from other mouse strains, we differentiated bone
marrow (BM) cells from Nc/Nga mice into DCs and treated
them with 1.0–25mg ml 1 of g-PGA in vitro. Following g-PGA
stimulation, the surface expression levels of activation markers
(e.g. CD40, CD80, CD86, and class II major histocom-
patibility complex MHC) were upregulated compared with
those in phosphate-buffered saline (PBS)–treated DCs
(Figure 1a). IL-12 secretion was increased by g-PGA in a
polymyxin B–independent manner, whereas lipopolysacchar-
ide-induced activation was almost completely abolished by
polymyxin B (Figure 1b). As previously reported (Lee et al.,
2009), DCs derived from C57BL/6 mice exhibited a similar
pattern of activation, in terms of surface markers and IL-12
secretion (data not shown). These data suggest that g-PGA
has a general potential for immunomodulation in both the
C57BL/6 background and in the Nc/Nga mouse model.
Oral administration of c-PGA alleviates AD symptoms in
Nc/Nga mice
On the basis of the observation that g-PGA induced IL-12
production from DCs in vitro (Figure 1), we postulated that
g-PGA could modulate AD, a Th2-driven skin disease, by
activating IFN-g production and inhibiting Th2 responses
in vivo. Consistent with a previous report (Matsuda et al.,
1997), Nc/Nga mice exposed to environmental aeroallergens
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Figure 1. Poly-c-glutamate (c-PGA) activates dendritic cells (DCs) to produce IL-12 in an Nc/Nga mouse model. DCs derived from bone marrow (BM) cells were
cultured in the presence of g-PGA or lipopolysaccharide (LPS). (a) DCs were harvested and the surface expression of CD40, CD80, CD86, and class II major
histocompatibility complex (MHC) was analyzed by flow cytometry. (b) The concentration of IL-12 in the culture media was determined by ELISA. Data are
presented as the mean±standard error of the mean (SEM), and representative of four independent experiments with similar results. Dex, dexamethasone; PBS,
phosphate-buffered saline; PMB, polymyxin B; w/o, without.
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under conventional conditions developed AD symptoms from
8 to 10 weeks of age. However, the mean clinical score of the
g-PGA (400mg per day) -treated group (1.7±1.9) was signi-
ficantly lower than that of the PBS-treated mice (6.8±1.1,
Po0.01) at week 14 (Figure 2a). The scratching counts in the
g-PGA group were also significantly lower than those in the
PBS- or Dex-treated groups (Figure 2b). Overall, only 40% of
mice in g-PGA group exhibited AD skin phenotypes, whereas
the incidence of AD in the other groups was more than 80%
(data not shown). Next, we examined the dose-dependent
effect of g-PGA by administering 100 to 800mg per day of
g-PGA to 8-week-old Nc/Nga mice. After 7 weeks of g-PGA
treatment, macroscopic observation of the skin revealed that
oral administration of high doses of g-PGA (400 and 800mg per
day) alleviated the disease symptoms, whereas lower doses of
g-PGA (100 and 200mg per day) had relatively little effect
(Figure 2c). Collectively, these data indicate that oral adminis-
tration of g-PGA efficiently suppresses the development or
progression of spontaneous AD in Nc/Nga mice.
Serum levels of IgE and IgG1 are negatively regulated by c-PGA
treatment
As AD is highly associated with elevated serum IgE levels and
Th2-predominant immune responses, we tested whether
g-PGA could modulate the serum levels of IgE, IgG1, and/or
IgG2a in Nc/Nga mice. In PBS-treated mice, the levels of IgE
gradually increased with age, reaching almost 1,400 ng ml 1
at 14 weeks. The g-PGA-treated mice, in contrast, displayed
relatively lower levels of total serum IgE (441±39.9 ng ml1,
about 0.32-fold) compared with the PBS-treated mice (P¼
0.061; Figure 3a). Similarly, g-PGA treatment substantially
decreased the IgG1 levels (550±66.6mg ml1) compared
with those of PBS-treated mice (1,351±69.9mg ml1;
Figure 3b). The Dex-treated group, a positive control, also
showed decreases in total serum IgE (289±61.0 ng ml1) and
IgG1 (566±45.5mg ml 1). Interestingly, the level of IgG2a
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Figure 2. Oral administration of poly-c-glutamate (c-PGA) alleviates atopic dermatitis (AD) symptoms in a dose-dependent manner. (a) Dermatitis index scores
were determined every 2 weeks as described in the Materials and Methods section, and are presented as the mean±SEM. Photographs showing representative
clinical characteristics were taken at week 15. (b) Scratching behavior was video recorded for 20 min and the episodes were manually counted in a blinded
manner. Data are presented as the mean±SEM. (c) Mice (n¼ 10 per group) were given different doses of g-PGA for 6 weeks, and their clinical symptoms were
monitored. Similar results were obtained from three independent experiments. Dex, dexamethasone; PBS, phosphate-buffered saline. *Po0.05, **Po0.01.
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Figure 3. Serum levels of IgE and IgG1 are negatively regulated by poly-c-
glutamate (c-PGA) treatment. Nc/Nga mice (n¼ 10 per group) were treated
with g-PGA (400mg per day) for 6 weeks, and serum samples were taken every
2 weeks for analysis. The levels of (a) serum IgE, (b) IgG1, and (c) IgG2a were
measured by ELISA. (d) After the 6-week-long treatments with different doses of
g-PGA, serum levels of IgE were evaluated by ELISA. All data are presented as
the mean±SEM and representative of three independent experiments. Dex,
dexamethasone; PBS, phosphate-buffered saline. *Po0.05, **Po0.01.
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was greatly increased in g-PGA-injected mice (453±
54.4mg ml1), but not in the PBS- nor Dex-treated groups
(227±28.0 and 208±50.6mg ml1, respectively). This indi-
cated that g-PGA not only suppressed Th2–type Igs, it also
enhanced the Th1-driven Ig, IgG2a (Figure 3c and d). When
the levels of serum IgE were measured after administration of
different doses of g-PGA (100–800mg per day), the groups
treated with 400 or 800mg of g-PGA showed decreases in
serum IgE levels (1,226±142.4 or 992±131.0 ng ml1,
respectively) compared with mice that received PBS or low
doses of g-PGA (Figure 3e). There was no significant difference
in the total IgE levels between mice treated with 400 versus
800mg of g-PGA (P¼ 0.43). These results collectively indicate
that oral administration of g-PGA negatively regulates
Th2-biased Ig production in vivo.
Administration of c-PGA reduces Th2 cytokines and IL-17A in
AD–like skin lesions
On the basis of the previous reports that Th2 cytokines such as
IL-4, IL-5, and IL-13 have critical roles in acute AD (Hamid
et al., 1994; Spergel et al., 1999; Vestergaard et al., 1999), we
next investigated whether g-PGA downregulates the production
of IL-4 and IL-5 at local inflammation sites of Nc/Nga mice.
Consistent with a previous report (Agarwal and Marshall, 2001),
IL-4 and IL-5 levels were substantially increased in the PBS-
treated group, but markedly suppressed by Dex. Treatment with
g-PGA (400mg per day) efficiently inhibited the massive
induction of Th2 cytokines in the inflamed skin, and to levels
comparable to those seen in the Dex-treated group (Figure 4a
and b). In addition to Th2 cytokines, IL-17A is closely involved
in the pathogenesis of AD and is present at high levels in AD
skin lesions (Toda et al., 2003; Koga et al., 2008). Measurement
of IL-17A in the skin revealed that these levels were
significantly lower in g-PGA-treated mice compared with
PBS–treated controls (100.6±19.3 vs. 186.5±45.1 pg per
100 mg tissue; Figure 4c), suggesting that g-PGA also suppresses
the potent proinflammatory cytokine, IL-17A.
Administration of c-PGA suppresses tissue inflammation and the
accumulation of mast cells in AD–like skin lesions
We next examined the microscopic changes and the extent of
immune cell infiltration in the skin tissue. When skin biopsies
were histologically examined after hematoxylin/eosin staining,
PBS–treated mice exhibited typical characteristics of AD, such
as hyperkeratosis, acanthosis, and parakeratosis (Figure 5a, left
panel). Tissue swelling and massive infiltrations of immune
cells were also observed in the skin lesions, coinciding with
the severe dermatitis symptoms shown in Figure 2. In contrast,
mice treated with g-PGA or Dex showed substantially less
tissue swelling and immune cell infiltration (Figure 5a, middle
and right panels, respectively). In particular, the accumulation
of mast cells in the upper dermis, which has a critical role in
the pathogenesis of AD, was significantly decreased in g-PGA-
treated mice compared with the PBS-treated group (180±56
vs. 380±70; Figure 5b, lower panel). These results suggest
that oral administration of g-PGA downregulates the infiltra-
tion and accumulation of immune cells into the skin lesions of
Nc/Nga mice, without apparent skin hypertrophy.
Administration of c-PGA has therapeutic effects on more severe,
established AD
Treatment with g-PGA was effective against low-severity AD
when it was administered from the onset of the disease. To
investigate whether g-PGA has a therapeutic effect on estab-
lished AD, Nc/Nga mice were kept for 18 weeks under the
conventional condition, allowing them to develop more
severe AD with higher clinical scores, and g-PGA (400mg
per day) was treated for 12 weeks. The AD progressed with
age, and the serum IgE levels gradually increased in the PBS–
treated group, consistent with the aggravation of AD symp-
toms over time (data not shown). The g-PGA-treated mice,
however, exhibited much slower increases in serum IgE,
indicating that g-PGA also negatively regulates IgE production
during the later phases of AD (Figure 6a). In terms of IgG, g-
PGA treatment led to the suppression of IgG1 and enhance-
ment of IgG2a (Figure 6b and c). Interestingly, although Dex
treatment was as efficient as g-PGA in downregulating IgE and
IgG1, it only insignificantly increased IgG2a (Figure 6a–c).
The effect of g-PGA on the systemic immune response
was also evaluated by analyzing cytokine production in
splenocytes at week 30. Upon stimulation with concanavalin
A, the expression of Th2 cytokines (e.g. IL-4, IL-5, and IL-10)
was greatly increased in PBS–treated mice compared with SPF
(specific pathogen free)–conditioned mice. However, g-PGA
or Dex treatment substantially decreased the levels of those
cytokines by about 35 to 50% (Figure 6a–c). Conversely, the
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levels of the Th1–type cytokines, IL-12 and IFN-g, were
significantly upregulated by g-PGA (Figure 6d and e). More
interestingly, the expression of IL-17A from splenocytes,
which is known to be markedly increased in AD patients
(Toda et al., 2003; Koga et al., 2008), was also markedly
decreased in g-PGA-treated mice compared with PBS–treated
mice (109±11.0 vs. 220±22.9 pg ml 1; Figure 6i). For all
parameters, SPF–conditioned Nc/Nga mice exhibited
significantly lower values compared with the groups kept
under conventional condition (Figure 6). These results
suggest that g-PGA not only ameliorates developing AD
but it also fights established disease by controlling systemic
immune responses.
DISCUSSION
AD is one of the main health problems in humans, negatively
influencing quality of life and causing economic burdens.
Based on reports that human AD is highly associated with
dysregulation of immune responses in terms of T helper
balance, recent studies have focused on Th2– or Th17–
targeting strategies. Here, we report the effect of g-PGA on
AD–like dermatitis in an Nc/Nga mouse model. Oral admin-
istration of g-PGA significantly reduced AD symptoms and the
levels of diverse AD–related markers, including IgE, IL-4, and
IL-17A. Histological examination revealed that g-PGA effi-
ciently suppressed the infiltration of inflammatory cells,
decreasing the level of skin inflammation. Furthermore, g-
PGA was also effective against established AD, suggesting that
it could be used as a therapeutic strategy against both
developing and developed AD in humans.
Excess Th2 immune response is highly associated with
pathogenesis of AD (Toda et al., 2003). Th17 subset also has
an important role in the pathogenesis of AD by secreting
proinflammatory cytokines, such as IL-17A and IL-22 (Koga
et al., 2008). In the present study, we found that g-PGA
efficiently induced IL-12 secretion from DCs in vitro
(Figure 1b), and suppressed expression of IL-4, IL-5, and
IL-17A in the AD skin lesions of Nc/Nga mice (Figure 4). As
IL-12 is a potent inducer of IFN-g, it is probable that IL-12
from activated DCs preferentially drives Th1 development
and suppresses Th2 and Th17 differentiation during T cell
activation in vivo. A previous study found that sustained
expression of exogenous IFN-g had an ameliorating effect in
the Nc/Nga AD model (Hattori et al., 2010). In addition, it
has been demonstrated that Th1–inducing agents, such as
CpG oligodeoxynucleotide, an extract from Actinidia arguta
(hardy kiwi) and a Streptococcus-derived fraction, displayed
therapeutic effects on AD in murine models (Horiuchi et al.,
2004; Inoue and Aramaki, 2007; Park et al., 2007). These
previous studies all support our interpretation that g-PGA
exerts its effect on AD by inducing Th1 response in our mice
model.
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Although the causative factor of AD is not defined yet, it
has been studied that filaggrin function and Th2 immune
response are closely related each other in murine models.
The flaky tail mice express relatively high levels of IgE and
Th17–related cytokines in a normal condition. When AD–
like skin disease spontaneously develops, Th2 immune
responses such as skin IL-4 and serum IgE are significantly
increased, whereas the level of IFN-g is sustained steadily
(Oyoshi et al., 2009). More interestingly, filaggrin
expression is downregulated in atopic Nc/Nga mice, and
suppression of Th2–dominant immune response reverses the
level of filaggrin (Howell et al., 2007; Kim et al., 2013).
Although we did not measure the filaggrin level after g-PGA
treatment, it was possible that suppression of Th2–biased
immune response by g-PGA affected the level of filaggrin
expression. Further studies will be needed to investigate the
effect of g-PGA on filaggrin expression or AD–like disease
in flaky tail mouse.
After oral administration of g-PGA, the immunomodulatory
effects have been studied in vivo murine models (Lee et al.,
2009), but the precise uptake mechanism of g-PGA is not yet
known. After oral administration of radioisotope (123Iodine) -
conjugated g-PGA, g-PGA in the serum was not detected but
excreted through digestive system and cleared up within
24 hours (unpublished data). Orally administered g-PGA may
be taken up by M-cells in the intestinal mucosa, as these cells
are able to uptake and transcytose diverse antigens to the
basolateral side, where diverse immune cells are recruited at a
high density (Neutra et al., 1996). Notably, a wide range of
inert particles and macromolecules (e.g. latex beads, alginate
microspheres, and horseradish peroxidase) can be taken up by
M-cells and presented to DCs beneath the intestinal
epithelium (Jepson et al., 1993; Gebert et al., 1996; Foster
et al., 1998; Clark et al., 2001). When we tested the effect of
topical application of g-PGA, we did not observe any
significant changes in clinical symptoms and serological
factors (data not shown). Further studies will be needed to
confirm the possible applications of g-PGA treatment.
Some bacteria such as Staphylococcus epidermidis and
Bacillus anthracis, which can be pathogenic in humans, also
produce g-PGA. However, g-PGA synthesized by these
microorganisms is quite different from that produced by B.
subtilis. Although B. subtilis secret soluble g-PGA, S. epider-
midis and B. anthracis produce surface-associated or capsular
form (Candela and Fouet, 2006). The capsular g-PGA contri-
butes to the resistance of S. epidermidis to harsh environ-
ments, and is considered as the virulence factor that help the
bacteria escape from the host immune system (Kocianova
et al., 2005). In this study, we used the soluble g-PGA purified
from B. subtilis, and proved its immunostimulatory property
in vitro (Figure 1). This strongly dispels the safety concerns
about the deleterious effect of g-PGA described above.
In this study, we found that g-PGA exhibited an efficacy
comparable to that of Dex in terms of ameliorating
clinical symptoms and downregulating Th2 responses.
Despite the potent efficacy of conventional chemicals against
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Figure 6. Oral administration of poly-c-glutamate (c-PGA) has therapeutic effects on established, higher severity atopic dermatitis (AD) in Nc/Nga mice.
Nc/Nga mice (n¼ 5 per group) were housed under conventional conditions for 18 weeks and then orally treated with phosphate-buffered saline (PBS),
dexamethasone (Dex) (50mg per day), or g-PGA (400mg per day) for an additional 12 weeks. (a–c) The levels of total IgE, IgG1, and IgG2a were determined
from serum samples, respectively. (d–i) Total splenocytes were stimulated with concanavalin A for 48 hours and the concentrations of IL-4, IL-5, IL-10,
IL-12, IFN-g, and IL-17A were measured from the culture media, respectively. All data are expressed as the mean±SEM. Similar results were obtained from
two independent experiments. SPF, specific pathogen free. *Po0.05, **Po0.01.
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AD, there are safety concerns regarding these drugs
(Barnetson and White, 1992; Leung and Barber, 2003;
Arellano et al., 2007). In contrast, g-PGA produced by
generally regarded as safe (GRAS) microorganisms is
considered safe and has long been consumed as a food
ingredient. Furthermore, a 13-week-long treatment with a
high dose of g-PGA (2.5 g kg1 per day) and daily ingestion of
g-PGA (50 g per person per day) for 8 weeks did not result in
any apparent abnormality in a rodent model (Sung et al.,
2005) and a clinical trial (unpublished data), respectively.
Moreover, unlike conventional chemotherapies, g-PGA
enhances the natural killer cell activity that is essential
for immune surveillance and protection against viral
infection (Kim et al., 2007); thus, concerns about systemic
immunosuppression can be dispelled. Notably, we observed
that the secretion of IL-12 and IFN-g from splenocytes was
significantly increased in g-PGA-treated mice but not in those
treated with Dex (Figure 6g and h).
In summary, we herein showed that oral administration of
g-PGA prevents the development of AD–like symptoms in Nc/
Nga mice and triggers remarkable changes in their immune
responses, as evidenced by decreased serum IgE levels and
reduced infiltration of mast cells to the atopic lesions.
Collectively, these results suggest that g-PGA could be a
promising immunotherapeutic candidate for the treatment of
human AD.
MATERIALS AND METHODS
Mice and reagents
Five-week-old male Nc/Nga mice were purchased from Japan SLC
(Hamamatsu, Japan) and housed under air-uncontrolled conventional
conditions or a SPF facility at Korea Research Institute of Bioscience
and Biotechnology (KRIBB, Daejeon, Republic of Korea). g-PGA
(average molecular weight 2,000 kDa) was kindly provided by
BioLeaders Corporation (Daejeon, Republic of Korea). This study
was performed according to the guidelines of the Animal Experiments
Ethics Committee at KRIBB.
Differentiation, treatment, and characterization of DCs
DCs were derived from BM cells as previously described (Lutz et al.,
1999), and cultured in the presence of 1.0–25mg ml 1 of g-PGA for
24 hours. The concentration of IL-12 in the culture media was
determined using an OptEIA kit (BD Biosciences, San Jose, CA).
After additional incubation for 24 hours, the cells were stained for
CD11b, CD11c, CD40, CD80, CD86, and class II major histocompa-
tibility complex. After fixation, samples were acquired on a Gallios
(Beckman Coulter, Indianapolis, IN) and data were analyzed using
FlowJo (TreeStar, Ashland, OR).
Administration of c-PGA
At week 8, the mice used for the acute developing AD model were
randomly divided into three groups (n¼ 10 per group) and orally
dosed with PBS, Dex (50mg per day), or g-PGA (400mg per day) for 7
weeks. To examine dose-dependent effect of g-PGA, each group
(n¼ 10 per group) was treated with 100, 200, 400, or 800mg per day
of g-PGA. For the established AD model, mice (n¼ 5 per group) were
treated with PBS, Dex (50mg per day), or g-PGA (400mg per day) for
12 weeks.
Clinical scoring of skin lesions
The total clinical severity score for skin lesions was calculated as the
sum of the individual scores (graded as 0 (none), 1 (mild), 2
(moderate), and 3 (severe)) for each of the five AD signs and
symptoms (itch, erythema/hemorrhage, edema, excoriation/erosion,
and scaling/dryness) (Suto et al., 1999).
Evaluation of scratching behavior
To evaluate scratching incidence, scratching behavior was recorded on
video for 20 minutes per mouse. A bout of scratching was defined as
three or more individual scratch movements (manually counted during
slow-motion replay) with the hind paws to the head, face, or back.
Measurement of serum Igs
Blood samples were collected from the retro-orbital plexus of each
mouse at the indicated time points. Total IgG1, IgG2a, and IgE were
determined by pairs of purified monoclonal capture and biotinylated
detection antibodies (BD Biosciences), according to the manufac-
turer’s instructions.
Cytokine ELISA
A total of 5 106 splenocytes were stimulated with 2mg ml 1
concanavalin A (Sigma-Aldrich, St Louis, MO) for 48 hours in a 12-
well plate. The culture supernatants were collected and stored at
 20 1C until use. Tissues from dorsal skin lesions were homogenized
in a lysis buffer (25 mM Tris-HCl, pH 7.4, containing 50 mM NaCl,
0.5% Na-deoxycholate, 2% NP-40, 0.2% SDS and protease inhibi-
tors), and then subjected to three rounds of freeze/thawing. The
concentrations of IL-10, IL-12, IFN-g, IL-4, and IL-5 in the super-
natants were determined using an OptEIA kit (BD Biosciences).
The levels of IL-17A were measured with an ELISA kit (BioLegend,
San Diego, CA) according to the manufacturer’s instructions.
Histological analysis
Dorsal skin specimens from Nc/Nga mice were fixed overnight in 4%
paraformaldehyde, embedded in paraffin, and sliced into 5-mm-thick
sections. The sections were deparaffinized and stained with hematox-
ylin/eosin for morphological examination or with 0.01% toluidine
blue for identification of mast cells. Histological analyses and mast
cell counting were performed in a blind manner.
Statistical analysis
The statistical differences between groups were assessed using a two-
tailed Student’s t-test or one-way analysis of variance with
Bonferroni–Dunn post hoc test. Within each treatment period,
changes in parameters (dermatitis index, number of scratchings per
20 min, serum levels of IgE, IgG1, and IgG2a) after PBS, g-PGA, or
Dex administration were tested using repeated-measures analysis of
variance with Greenhouse–Geisser or Wilks’ l correction. A P-value
o0.05 was considered statistically significant.
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